• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Levonorgestrel IUD vs Endometrial Ablation for Heavy Menstrual Bleeding

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Beelen et al. (AJOG, 2020) compared the effectiveness of the levonorgestrel-releasing IUD with endometrial ablation in women with heavy menstrual bleeding

METHODS:

  • Multicenter, randomized controlled, noninferiority trial
  • Participants
    • Heavy menstrual bleeding and no intracavitary pathology
    • ≥34 years
    • Does not desire pregnancy
  • Interventions
    • Levonorgestrel IUD (Mirena)
    • Endometrial ablation with a bipolar radiofrequency device (NovaSure)
  • Statistical analysis
    • Blood loss based on Pictorial Blood Loss Assessment Chart (PBAC) score
    • 50 point difference in PBAC score considered clinically meaningful
    • Expert panel, using previous studies and clinical judgment difference, determined that “noninferiority of the LNG-IUS treatment would be shown if the upper limit of the 95% CI for the difference in PBAC score did not exceed the predetermined noninferiority margin of 25 points, with a corresponding P value of <.05”
  • Primary outcome
    • Blood loss at 24 months
  • Secondary outcomes
    • Reintervention rates
    • Patient satisfaction and quality of life
    • Sexual function

RESULTS:

  • IUD group: 132 women | EA group: 138 women
  • Mean PBAC score decreased substantially in both groups within the first 3 months
    • IUD group: 616.3 to 120.8
    • EA group: 630.0 to 59.2
  • Women in the EA group had lower mean blood loss scores at 24 months
    • IUD group: 64.8 mean blood loss score
    • EA group: 14.2
    • Difference 50.5 points (95% CI, 4.3 to 96.7)
    • Upper limit of the 95% CI exceeds the noninferiority margin of 25 points | Noninferiority of the IUD was not demonstrated
  • Women in the IUD group were at a higher risk of undergoing a surgical reintervention
    • IUD: 27% (34 women)
    • EA: 10% (14 women)
    • Relative risk 2.64 (95% CI, 1.49 to 4.68)
  • There was no significant difference in patient satisfaction and quality of life between the groups

CONCLUSION:

  • Women in both groups experienced a large decrease in menstrual blood loss after intervention
  • EA did result in a greater decrease in blood loss over the levonorgestrel IUD (noninferiority was not demonstrated) and women who started with the IUD were more likely to need a surgical reintervention
  • Quality of life scores were comparable between the two groups
  • The authors conclude

The results of this study will enable physicians to provide women with clear information about multiple important outcomes after HMB treatment

For instance, the faster reduction in menstrual blood loss and lower chance of needing additional treatment of EA can be weighed against the less-invasive and reversible characteristics of the LNG-IUS

Learn More – Primary Sources:

Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is Heavy Menstrual Bleeding a Sign of a Bleeding Disorder in Adolescents?
Cochrane Review 2020: Are Progestogen-Releasing IUDs Effective for Managing Heavy Menstrual Bleeding?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site